{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:42:25Z","timestamp":1787805745724,"version":"build-2784847793"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Individuals living with human immunodeficiency virus (HIV) who experience virological failure (VF) after combination antiretroviral therapy (cART) initiation may have had low-frequency drug resistance mutations (DRMs) at cART initiation. There are no data on low-frequency DRMs among cART-na\u00efve HIV-positive individuals in Botswana.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We evaluated the prevalence of low-frequency DRMs among cART-na\u00efve individuals previously sequenced using Sanger sequencing. The generated pol amplicons were sequenced by next-generation sequencing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We observed low-frequency DRMs (detected at &lt;20% in 33\/103 (32%) of the successfully sequenced individuals, of whom four also had mutations detected at &gt;20%. K65R was the most common low-frequency DRM detected in 8 individuals. Eighty-two of the 103 individuals had follow-up viral load data while on cART. Twenty-seven of the 82 individuals harbored low-frequency DRMs. Only 12 of 82 individuals experienced VF. The following low-frequency DRMs were observed in four individuals experiencing VF: K65R, K103N, V108I, and Y188C. No statistically significant difference was observed in the prevalence of low-frequency DRMs between individuals experiencing VF (4\/12) and those not experiencing VF (23\/70) (<jats:italic toggle=\"yes\">P<\/jats:italic> = .97). However, individuals with non-nucleoside reverse transcriptase inhibitors-associated low-frequency DRMs were 2.68 times more likely to experience VF (odds ratio, 2.68; 95% confidential interval, 0.4\u201313.9) compared with those without (<jats:italic toggle=\"yes\">P<\/jats:italic> = .22).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Next-generation sequencing was able to detect low-frequency DRMs in this cohort in Botswana, but these DRMs did not contribute significantly to VF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029577","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:11:32Z","timestamp":1662649892000},"page":"e29577","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Low-frequency HIV-1 drug resistance mutations in antiretroviral na\u00efve individuals in Botswana"],"prefix":"10.1097","volume":"101","author":[{"given":"Dorcas","family":"Maruapula","sequence":"first","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"Department of Biological Sciences, University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaelo K.","family":"Seatla","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"School of Allied Health Professions, University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olorato","family":"Morerinyane","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesaobaka","family":"Molebatsi","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"Department of Statistics, University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Giandhari","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary M.","family":"Musonda","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Leteane","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sununguko W","family":"Mpoloka","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Rowley","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-3735","authenticated-orcid":false,"given":"Simani","family":"Gaseitsiwe","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"Collaboration","year":"2010","journal-title":"AIDS"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e0206796e0206796","DOI":"10.1371\/journal.pone.0206796","article-title":"Ten years of antiretroviral therapy: incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort","volume":"13","author":"Weissberg","year":"2018","journal-title":"PLoS One"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"115115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"\u00c1vila-R\u00edos","year":"2016","journal-title":"Lancet HIV"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00705-016-2955-z","article-title":"Antiretroviral drug resistance mutations in na\u00efve and experienced patients in Shiraz, Iran, 2014","volume":"161","author":"Naziri","year":"2016","journal-title":"Arch Virol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1016\/S2214-109X(18)30218-3","article-title":"Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.","volume":"6","author":"Zash","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19801-x","article-title":"Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase","volume":"11","author":"Siedner","year":"2020","journal-title":"Nat Commun"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/COH.0000000000000376","article-title":"Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings","volume":"12","author":"Maartens","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0b013e32835b7f94","article-title":"Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa","volume":"8","author":"Hamers","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","article-title":"Clinical management of HIV-1 resistance","volume":"85","author":"Paredes","year":"2010","journal-title":"Antiviral Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000000267","article-title":"Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure","volume":"28","author":"Mohamed","year":"2014","journal-title":"AIDS"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an in vitro diagnostic next-generation sequencing assay with sanger sequencing for HIV-1 genotypic resistance testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R17-20250504","first-page":"187","article-title":"Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries","volume":"16","author":"Samuel","year":"2014","journal-title":"AIDS Rev"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.coviro.2011.07.008","article-title":"Ultra-deep sequencing for the analysis of viral populations","volume":"1","author":"Beerenwinkel","year":"2011","journal-title":"Curr Opin Virol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1128\/AAC.01490-15","article-title":"HIV drug resistance testing by high-multiplex \u201cwide\u201d sequencing on the MiSeq instrument","volume":"59","author":"Lapointe","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/jmv.25224","article-title":"Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene","volume":"90","author":"Nicot","year":"2018","journal-title":"J Med Virol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12977-014-0122-8","article-title":"Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq","volume":"11","author":"Dudley","year":"2014","journal-title":"Retrovirology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45328-3","article-title":"A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance","volume":"9","author":"Taylor","year":"2019","journal-title":"Sci Rep"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcv.2014.06.013","article-title":"Deep sequencing: becoming a critical tool in clinical virology","volume":"61","author":"Qui\u00f1ones-Mateu","year":"2014","journal-title":"J Clin Virol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.virusres.2016.10.019","article-title":"Deep sequencing for HIV-1 clinical management","volume":"239","author":"Casadell\u00e0","year":"2017","journal-title":"Virus Res"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(16)30118-9","article-title":"Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa","volume":"16","author":"Inzaule","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"e86771","DOI":"10.1371\/journal.pone.0086771","article-title":"Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure","volume":"9","author":"Vandenhende","year":"2014","journal-title":"PLoS One"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment\u2013na\u00efve populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/595703","article-title":"Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients","volume":"48","author":"Metzner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R31-20250504","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes","year":"2010","journal-title":"J Infect Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/jac\/dkx232","article-title":"RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients","volume":"72","author":"Alidjinou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case\u2013control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00038-16","article-title":"Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure","volume":"60","author":"Kyeyune","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jmv.23853","article-title":"Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients","volume":"86","author":"Mohamed","year":"2014","journal-title":"J Med Virol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/cid\/cit125","article-title":"Clinical implications of HIV-1 minority variants","volume":"56","author":"Li","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/aid.2009.0082","article-title":"Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance","volume":"26","author":"Rowley","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1105688108","article-title":"Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine","volume":"108","author":"Boltz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","article-title":"Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome","volume":"50","author":"Jakobsen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jac\/dkab062","article-title":"Impact of pre-existing drug resistance on risk of virological failure in South Africa","volume":"76","author":"Li","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e32834e9d7d","article-title":"Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure","volume":"26","author":"Li","year":"2012","journal-title":"AIDS"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/infdis\/jit635","article-title":"Low-frequency nevirapine (NVP)\u2013resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP","volume":"209","author":"Boltz","year":"2014","journal-title":"J Infect Dis"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/jac\/dku470","article-title":"Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon","volume":"70","author":"Zoufaly","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkv500","article-title":"Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance.","volume":"71(5)(1460-2091 (Electronic))","author":"Rowley","year":"2016","journal-title":"Antimicrob Chemother"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/bioinformatics\/bty695","article-title":"Genome detective: an automated system for virus identification from high-throughput sequencing data","volume":"35","author":"Vilsker","year":"2019","journal-title":"Bioinformatics"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"Kearse","year":"2012","journal-title":"Bioinformatics"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/sim.4780141908","article-title":"Exact logistic regression: theory and examples","volume":"14","author":"Mehta","year":"1995","journal-title":"Stat Med"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/sim.4780080704","article-title":"Sample size tables for logistic regression","volume":"8","author":"Hsieh","year":"1989","journal-title":"Stat Med"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/pathogens10030264","article-title":"HIV drug resistance mutations detection by next-generation sequencing during antiretroviral therapy interruption in China","volume":"10","author":"Li","year":"2021","journal-title":"Pathogens"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1093\/jac\/dkaa343","article-title":"Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1\/TB-co-infected individuals","volume":"75","author":"Chimukangara","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00705-010-0659-3","article-title":"Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART","volume":"155","author":"Lopez","year":"2010","journal-title":"Arch Virol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"4979252","DOI":"10.1155\/2017\/4979252","article-title":"A robust PCR protocol for HIV drug resistance testing on low-level viremia samples","volume":"2017","author":"Gupta","year":"2017","journal-title":"Biomed Res Int"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0000000000001964","article-title":"HIV second-line failure and drug resistance at high-and low-level viremia in Western Kenya","volume":"32","author":"Kantor","year":"2018","journal-title":"AIDS"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0000000000002166","article-title":"Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana. AIDS","volume":"33","author":"Moyo","year":"2019","journal-title":"(London, England)"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2009.03.002","article-title":"Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure","volume":"45","author":"Balduin","year":"2009","journal-title":"J Clin Virol"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"e130118","DOI":"10.1172\/jci.insight.130118","article-title":"Linked dual-class HIV resistance mutations are associated with treatment failure","volume":"4","author":"Boltz","year":"2019","journal-title":"JCI Insight"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"e0210559","DOI":"10.1371\/journal.pone.0210559","article-title":"Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya","volume":"14","author":"Hassan","year":"2019","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:14:33Z","timestamp":1746332073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":55,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029577","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}